UTI MNC Fund
The scheme seeks to generate long term capital appreciation by investing predominantly in equity and equity related securities of multinational companies.
Growthvine rating: 3/5 — ranked #58 of 186 in category.
Fund basics
| Category | Equity: Thematic |
|---|
| NAV | ₹363.13 (as of 2026-10-23) |
|---|
| AUM | ₹2,619 Cr |
|---|
| Expense ratio | 1.70% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Karthikraj Lakshmanan |
|---|
| Exit load | 1% for redemption within 364 days |
|---|
Performance & risk
| 5-year annualised return | 6.50% |
|---|
| Sharpe ratio | 0.17 |
|---|
| Standard deviation | 15.00% |
|---|
| Max drawdown | −48.01% |
|---|
| Alpha | -1.49 |
|---|
| Beta | 0.91 |
|---|
Over 5 years, captured 38.8% of NIFTY CPSE's upside and 52.7% of its downside.
Market cap allocation
| Large cap | 31.7% |
|---|
| Mid cap | 31.1% |
|---|
| Small cap | 37.2% |
|---|
Concentration
| Top 5 holdings | 26.6% |
|---|
| Top 10 holdings | 41.7% |
|---|
| Total holdings | 58 |
|---|
Top holdings
- Maruti Suzuki India Ltd. — 7.2%
- NET CURRENT ASSETS — 6.3%
- Bosch Ltd — 5.8%
- Nestle India Ltd. — 4.8%
- Hindustan Unilever Ltd. — 4.7%
- Gland Pharma Limited — 4.1%
- PROCTER & GAMBLE HEALTH LIMITED — 4.0%
- HYUNDAI MOTOR INDIA LIMITED — 3.1%
- Vedanta Aluminium Metal Limited — 2.9%
- LG Electronics India Limited — 2.6%
Top sectors
- Automobile — 22.8%
- Pharma & Biotech — 16.1%
- Software & Services — 10.6%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | −10.0% | Q3 | #116 of 167 |
| 2025 | 3.4% | Q3 | #71 of 132 |
| 2024 | 16.7% | Q3 | #63 of 86 |
| 2023 | 22.6% | Q4 (Bottom) | #61 of 66 |
| 2022 | −1.4% | Q3 | #38 of 55 |